Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | Prevention of progression: ixazomib/len/dex in high-risk SMM

Irene Ghobrial • 8 Dec 2019
ASH 2019
Multiple Myeloma Rare Diseases Smoldering Myeloma Dexamethasone Ixazomib Lenalidomide

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the phase 2 trial aimed to determine the progression-free survival and response rate of early therapeutic intervention in patients with high-risk smoldering multiple myeloma (SMM) using the combination of ixazomib, lenalidomide and dexamethasone. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Irene Ghobrial

Risk stratification in smoldering myeloma: current standards and emerging advances 1:05
Risk stratification in smoldering myeloma: current standards and emerging advances
Irene Ghobrial • 17 Sep 2025
Controversies and unanswered questions in smoldering myeloma and MGUS 0:53
Controversies and unanswered questions in smoldering myeloma and MGUS
Irene Ghobrial • 17 Sep 2025
The potential of circulating tumor cells to clinically assess multiple myeloma and its precursors 0:51
The potential of circulating tumor cells to clinically assess multiple myeloma and its precursors
Irene Ghobrial • 17 Sep 2025
Wrap-up of the 2025 Intercepting Blood Cancers Workshop 0:50
Wrap-up of the 2025 Intercepting Blood Cancers Workshop
Irene Ghobrial • 13 Mar 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals